Chimerix Inc. (NASDAQ:CMRX) was up 2.3% during trading on Monday . The stock traded as high as $4.48 and last traded at $4.41, with a volume of 239,714 shares. The stock had previously closed at $4.31.

Several equities research analysts have commented on CMRX shares. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Wednesday, August 10th. Piper Jaffray Cos. set a $12.00 price objective on Chimerix and gave the stock a “buy” rating in a research note on Thursday. FBR & Co reiterated a “hold” rating on shares of Chimerix in a research note on Sunday, July 17th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and set a $7.00 price objective on shares of Chimerix in a research note on Tuesday, August 9th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $15.72.

The company’s 50-day moving average price is $4.13 and its 200-day moving average price is $4.96. The firm’s market cap is $217.67 million.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.12. The firm earned $1.80 million during the quarter, compared to analyst estimates of $1.98 million. On average, equities analysts anticipate that Chimerix Inc. will post ($1.78) EPS for the current fiscal year.

In related news, Director Ernest Mario purchased 50,000 shares of Chimerix stock in a transaction dated Friday, June 24th. The stock was bought at an average cost of $3.70 per share, for a total transaction of $185,000.00. Following the transaction, the director now owns 381,440 shares in the company, valued at $1,411,328. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO M Michelle Berrey purchased 13,188 shares of Chimerix stock in a transaction dated Friday, June 24th. The shares were bought at an average price of $3.69 per share, with a total value of $48,663.72. Following the completion of the transaction, the chief executive officer now owns 258,821 shares in the company, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Chimerix stock. Jennison Associates LLC increased its position in shares of Chimerix Inc. (NASDAQ:CMRX) by 67.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,273,779 shares of the biopharmaceutical company’s stock after buying an additional 515,029 shares during the period. Jennison Associates LLC owned 2.76% of Chimerix worth $11,400,000 as of its most recent filing with the SEC.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.